| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
REVEAL pivotal and ASPIRE trials evaluating TSHA-102 for Rett syndrome ongoing; expect to report topline data from 6-month interim analysis and FDA feedback on BLA submission pathway in 1H 2027 |
| 12 Nov 2026 | 10-Q |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 11 Aug 2026 | 10-Q |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6-month interim analysis and FDA feedback on the BLA submission pathway in 1H 2027 |
| 10 Jul 2026 |
Form 4: Nagendran Sukumar, Director
Sold 200,000 shares ($1.25M) |
| 10 Jul 2026 | 144 |
| 25 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underw... |
| 25 Jun 2026 | 424B5 |
| 24 Jun 2026 | 424B5 |
| 22 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
TSHA-102 Rett Syndrome program Update: Longer-term Results from REVEAL Phase 1/2 trials June 2026 Exhibit 99.2 |
| 02 Jun 2026 |
Form 4: Stalfort John A Iii, Director
Received 21,335 shares as a grant or award · Granted 42,671 Stock Option (right to buy) |
| 02 Jun 2026 |
Form 4: Long Alison S, Director
Received 21,335 shares as a grant or award · Granted 42,671 Stock Option (right to buy) |
| 02 Jun 2026 |
Form 4: Sepp-Lorenzino Laura, Director
Received 21,335 shares as a grant or award · Granted 42,671 Stock Option (right to buy) |
| 02 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 1, 2026, Taysha Gene Therapies, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders considered four proposals, each of which is described in more detai... |
| 02 Jun 2026 |
Form 4: Donenberg Phillip B., Director
Received 21,335 shares as a grant or award · Granted 42,671 Stock Option (right to buy) |
| 15 May 2026 | SCHEDULE 13G/A |
| 15 May 2026 | SCHEDULE 13G/A |
Loading...